1

ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients

Yufeng Song[1], Regan Myers[1], Lila Murphy[1,2], Bailey Brooks[1,2], Jeffrey M. Wilson[3],

Alexandra Kadl[4,5], Judith Woodfolk[4],Steven L. Zeichner[1,6]*

[1]Department of Pediatrics, University of Virginia

[2]College of Arts and Sciences, University of Virginia

[3]Division of Allergy and Clinical Immunology, Department of Medicine, University of

Virginia

[4]Department of Medicine, University of Virginia

[5]Department of Pharmacology, University of Virginia

[6]Department of Microbiology, Immunology, and Cancer Biology, University of Virginia

*Correspondence: zeichner@virginia.edu

## Abstract

Many mechanisms responsible for COVID-19 pathogenesis are well-established, but COVID-19 includes features with unclear pathogenesis, such as autonomic dysregulation, coagulopathies, and high levels of inflammation. The receptor for SARS-CoV-2 spike protein's receptor binding domain (RBD) is angiotensin converting enzyme 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that have negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like catalytic activity – ACE2-like abzymes. To explore this hypothesis, we studied patients hospitalized with COVID-19 who had plasma samples available obtained about 7 days after admission. ACE2 is a metalloprotease that requires $Zn^{2+}$ for activity. However, we found that the plasma  from some patients studied could cleave a synthetic ACE2 peptide substrate, even though the plasma samples were collected using disodium ethylenediaminetetraacetate (EDTA) anticoagulant. When we spiked plasma with synthetic ACE2, no ACE2 substrate cleavage activity was observed unless $Zn^{2+}$ was added or the plasma was diluted to decrease EDTA concentration. After processing samples by 100 kDa size exclusion columns and protein A/G adsorption, which depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2 substrate peptide. The data suggest that some patients with COVID-19 develop antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since abzymes can exhibit promiscuous substrate specificities compared to the enzyme whose active site image they resemble, and since proteolytic cascades regulate many physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure COVID-19 pathogenesis.

## Introduction

The primary pathology in COVID-19 involves pulmonary disease[1-3]. Other end organ involvement, likely directly attributable to infection with the virus, can include gastrointestinal disease, such as diarrhea, and loss of smell and taste[2-4]. While the basic pathophysiology of COVID-19 is well-established, COVID-19 has many baffling features, including disorders involving high inflammation, disorders of the clotting cascade, and problems with blood pressure homeostasis[2, 5, 6]. Some sequelae do not develop until a week or more after infection, suggesting that their pathogenesis may result from secondary processes.

Reports suggest that some of the inflammatory processes associated with COVID-19 may relate to antibodies against the SARS-CoV-2 spike protein, S. For example, small numbers of children who have received COVID-19 vaccines and have had no evidence of infection with SARS-CoV-2, as well as a small number of infants born to mothers with COVID-19[8] have been described as having multi-system inflammatory syndrome of children (MIS-C)[7].

In addition to acute COVID-19, some patients experience Post-Acute Sequelae of SARS CoV-2 infection (PASC, sometimes called "long COVID"), a heterogeneous group of symptoms that continue after acute infection has resolved and can include evidence of a hyperinflammatory state[9], persistent coagulopathies, and neurophysiologic dysregulation, for example aberrant blood pressure regulation. While some clinical features observable at the beginning of the COVID-19 clinical course, such as SARS-CoV-2 viremia, autoantibodies, inflammatory markers, and activation of Epstein-Barr

Virus, may be associated with an increased risk of long COVID[10], the detailed

pathogenic processes responsible for PASC remain unclear.

Membrane-bound angiotensin converting enzyme 2 (ACE2) is the main cellular receptor

for SARS-CoV-2. Binding of the SARS-CoV-2 spike protein receptor binding domain

(RBD) to ACE2 initiates the pathway that leads to infection of a new host cell. ACE2, a

$Zn^{2+}$ metalloenzyme, cleaves angiotensin II into angiotensin 1-7, which has vasodilatory

activity. Angiotensin converting enzyme (ACE) cleaves angiotensin I to yield angiotensin

II, which has vasoconstrictive and hypertensive effects. ACE2 therefore helps to

counteract the hypertensive effects of angiotensin II, and so has blood pressure

counterregulatory activity compared to ACE. There have been isolated reports and

small case series describing persistent hypotension in patients with COVID-19 and

patients with PASC without a clearly identified cause[11-13].

The kallikrein-kinin system is a proteolytic cascade that helps regulate inflammation

(reviewed in [14]). There is cross-talk between the coagulation, kallikrein-kinin,

complement and renin-angiotensin systems[15]. Some patients with severe COVID-19

respiratory disease have been found to have altered regulation of the kallikrein-kinin

system in bronchoalveolar lavage fluid[16]. Abnormalities in the kallikrein-kinin system

have been proposed as contributing to the pathogenesis of severe COVID-19[17].

Catalytic antibodies, "abzymes"[18, 19], are antibodies that have catalytic activity. When

abzymes were first described, they generated considerable excitement. Investigators

hypothesized that it would be possible to produce clinically and biotechnologically useful

abzymes.

However, with additional studies, it became clearer that abzyme activity was

significantly lower than the activity of more conventional enzymes ($k$cat/$Km$ values ~$10^2$

- $10^4$ s$^{-1}$•M s$^{-1}$ [20] vs. $k$cat/$Km$ values of ~$10^5$ s$^{-1}$•M s$^{-1}$)[21]. Hence, interest in the

biotechnological applications of abzymes waned, but an appreciation of the potential

role of abzymes in the pathogenesis of disease, including autoimmune disease,

increased. High concentrations of abzymes in the circulation may compensate for the

abzymes' lower activity to yield clinically significant effects.

Patients with autoimmune diseases can make abzymes catalyzing, for example,

cleavage of vasoactive intestinal peptide (VIP)[22], DNA[23], immunoglobulin components[24],

components of the clotting cascade[25-27], and myelin basic protein (MBP) in patients with

multiple sclerosis[28]. Abzymes that cleave the HIV envelope protein have been observed

to occur in patients with HIV, so there is precedence for the induction of a catalytic

antibody by a virus[29].

Investigators have deliberately made anti-idiotypic abzymes with catalytic activity like

the activity of a particular enzyme of interest[30, 31]. Investigators identify an antibody

against an enzyme, and then produce an antibody against the anti-enzyme antibody.

For some of the anti-idiotypic antibodies, there is enough resemblance to the active site

of the enzyme that the anti-idiotypic antibody has catalytic activity resembling the

enzyme[32, 33]. In some instances, the substrate specificity of the abzyme differs

substantially from that of the original enzyme[31, 32, 34], with the abzyme showing more

substrate promiscuity than the original enzyme.

The receptor binding domain of the SARS-CoV-2 spike protein uses the ACE2 enzyme

on the surface of the target future host cell as its receptor. The RBD is not an antibody,

but it does bind ACE2. Taking as an example of abzyme production the anti-idiotypic

antibody to an antibody against an enzyme, it is plausible to hypothesize that in some

cases, an antibody against the RBD might resemble the ACE2 active site and so have

catalytic activity. If an antibody directed against the RBD has some resemblance to

ACE2, it is also plausible that anti-RBD antibodies, for some small fraction of patients,

might have catalytic activity reminiscent of ACE2. We hypothesized that some COVID-

19 patients may develop anti-RBD antibodies, with promiscuous catalytic activity that, in

some cases, cleaves substrates in patients to yield clinically significant effects. FIG 1

outlines this hypothesis schematically. We therefore undertook a study to explore

whether some COVID-19 patients might have antibodies that can cleave an ACE2

substrate.

We studied plasma samples from a group of 67 patients, with samples obtained

relatively early in their disease course, on about the 7th day of hospitalization. We

tested plasma using an established fluorometric assay for ACE2 activity, which detects

cleavage of an ACE2 peptide substrate. We found that some of the patients had ACE2

substrate peptide cleavage activity when the assay was run directly on disodium

ethylenediaminetetraacetate (EDTA)-anticoagulated plasma samples, even though

ACE2 is a metalloprotease that requires $Zn^{2+}$ for activity. Recombinant ACE2 added to

plasma did not show ACE2 substrate-cleaving activity unless $ZnCl_2$ was added to

samples at concentrations greater than the EDTA. Processing the samples through a

100 KDa size exclusion column followed by absorption with protein A/G beads, which

depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2

peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may

develop antibodies that have ACE2 substrate cleavage activity.

## Methods

**Clinical Cohort**

The clinical cohort was recently described in more detail in another publication[35]. The hypothesis motivating that work held that COVID-19 would lead to large scale reactivation of lymphotrophic herpesviruses EBV and HHV-6, but the data obtained in the study did not support that hypothesis. In brief, the University of Virginia (UVA) enrolled a prospective cohort of moderate to severe COVID-19 adult patients admitted to the hospital with a diagnosis confirmed by a nucleic acid amplification test. Patients consented were entered into the study. Clinical data were entered into study databases. Plasma was collected into clinical standard lavender top (EDTA anticoagulant) tubes. Samples were processed in the UVA Biorepository and Tissue Facility and stored at -80 C. Study participants (n=67) were adults ages 18 years and above. We used samples obtained on or about day 7 of hospitalization for this study, prior to anti-inflammatory drug administration. The predominant viral strain for our sample was the alpha strain with 98.51% of our sample (66 patients) being collected before July of 2021.The sample collection protocol was approved by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens (HSR #HSR200362), and it follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. EDTA-anticoagulated healthy normal donor plasma was purchased from Valley Biomedical (Cat. #HP1051P), aliquoted and stored in -20℃ according to manufacturer's instructions.

**Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection**

Abzyme catalytic activities in plasma samples were measured using an Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)

according to the manufacturer's protocol. This assay employs a synthetic ACE2 peptide

substrate labeled with a fluor and a quencher. The manufacturer's product information

claims a lower limit of detection for an unmodified assay of 400 µU. The manufacturer

does not release detailed information concerning the peptide substrate, holding that

information as a trade secret. The kit includes recombinant human ACE2 (ACE2) for

use as a positive control. $50\mu l$ plasma was added to wells in a 96-well black flat bottom

assay plate (Corning, Cat. #3603) and incubated at room temperature (RT), in the dark

for 15 min. Then, $50\mu l$ of substrate pre-diluted according to manufacturer's protocol was

added into the wells of the plate, mixing the substrate with the plasma sample. The

plate was immediately placed into a SpectraMax® M5 multi-model microplate reader

(Molecular Devices) and the Relative Fluorescent Unit (RFU, Ex/Em = 320/420 nm)

values were measured in kinetic mode every 20 min for a total of 16 hours at 37℃.

ACE2 inhibitor provided in the assay kit was also used for additional controls.

**Determination of ACE2 Substrate Peptide Cleavage Activity in Plasma Samples**

**With and Without Added ZnCl$_2$ or Plasma Dilution**

To evaluate whether native ACE2 shed into blood[36, 37] could contribute to the catalytic

activity observed in the patient plasma samples, we investigated whether EDTA present

in the plasma samples inhibited activity of recombinant ACE2 spiked into the samples.

EDTA can inhibit the catalytic activity of ACE2, a $Zn^{2+}$ metaloprotease[38, 39].

We conducted serial 10-fold dilutions of the normal donor plasma in ACE2 assay buffer

from the assay kit and then added and then added 2 $\mu L$ recombinant positive control

ACE2, provided as a positive control in the ACE2 assay kit (Abcam, Cat. #ab273297) to

each well to the samples to the samples according to the manufacturer's protocol,

conducting the ACE2 assays on the serially diluted samples with the added

recombinant ACE2. We also added $ZnCl_2$ to some samples to achieve final

concentrations ranging from 0 to 2 mM. Samples containing plasma, recombinant ACE2

and $ZnCl_2$ mixture with pre-diluted ACE2 inhibitor served as negative comparisons.

Then, 50 $\mu$L of substrate (pre-diluted according to manufacturer's protocol) was added

into the wells. Relative Fluorescent Units were measured, and data was analyzed as

described below.

**Human IgG Depletion and Detection**

To deplete immunoglobulin from the samples, patient plasma samples or pooled healthy

donor plasma were centrifuged at 12,000 g at 4 ℃ for 15 min and supernatants were

passed through 0.45 $\mu$m syringe filter (FisherScientific, Cat. #97204) to remove

contaminating particulate matter. We then placed 500 $\mu$L of the filtered samples into

ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #

88503) and centrifuged the columns at 12,000 × g at 4 ℃ until > 400 $\mu$L of filtrate was

produced. To further deplete antibodies in the plasma samples, we then incubated the

flow-through fractions with 30 $\mu$L pre-washed Protein A/G Magnetic Beads (Life

Technologies, Cat. # 88803, 10 mg/mL) at room temperature (RT) for 1 hour, followed

by magnetic removal of the beads, and repeated the same incubation procedure with

another freshly prepared 30 $\mu$L magnetic beads. The resulting processed plasma

samples were stored at 4℃ for short times (less than 12 hours) or -20 ℃ for longer

times. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.

#ab100547) according to the manufacturer's protocol. We added 50 $\mu$L processed

samples, as well as standards to multi-microwell strips and incubated them at room

temperature for 2.5 hours. Strips were washed with wash buffer and 50 $\mu$L diluted

biotin-labeled IgG detection antibody were then added to each well with subsequent

HRP-streptavidin incubation after another wash step. Each incubation was performed at

room temperature for at least 1 hour. After washing, 100 $\mu$L of TMB One-Step Substrate

was added to each well and was incubated for 5 to 15 min at room temperature in the

dark with gentle shanking. The reaction was stopped by adding 50 $\mu$L Stop Solution to

each well. OD values were read at 450 nm using an accuSkan FC micro-well plate

reader (ThermoFisher). IgG concentrations were calculated based on standard curves

generated with the same batch of assay strips.

**Data Analysis**

Since the RFU values for the assays conducted on the samples reached 80% of

maximum at about 240 min, RFU values observed over 240 min generated by an ACE2

kit were used to evaluate ACE2 substrate cleavage activity in the plasma samples. For

each sample, a value corrected for baseline fluorescence in the sample was obtained

by the subtracting the baseline RFU value from the value at each subsequent time and

the sum of the baseline-corrected RFU values over 240 min was calculated using Excel.

Subsequent statistical analysis and data visualization was done using R (version 4.2.1)

with the Rstudio environment and packages ggplot2, tidyverse, readr, drc, ggpubr,

ggh4x, gridExtra, and scales. Raw data and R scripts used in the analysis are provided

in Supplementary Data (S1, S2). Samples with the top 20% and a control bottom 10%

RFU values over 240 min were identified for antibody depletion and further assays.

**Results**

To develop assays with enhanced sensitivity for ACE2 substrate cleavage activity, we used a commercially available kit, in which a synthetic peptide ACE2 substrate labeled with a fluor and a quencher is exposed to sample. ACE2 substrate cleavage  activity frees the fluor from quenching, followed by fluorometric evaluation over time. We first established the kit's performance characteristics on commercially purchased EDTA-anticoagulated normal human plasma. ACE2 is as $Zn^{2+}$-requiring metalloenzyme. Since EDTA was used as the anticoagulant, to make $Zn^{2+}$ unavailable to the $Zn^{2+}$-requiring metalloenzymes of the enzymes involved in the coagulation cascade, we first established whether exogenously added ACE2 could be detected when added to plasma samples under our assay conditions. We found that exogenously added recombinant ACE2 could not be detected, either using commercially obtained pooled plasma or in plasma samples pooled from our patients and obtained from our sample bank, unless $Zn^{2+}$ was added or unless the plasma was diluted (FIG 2). Since no native ACE2 activity should be detectable in the EDTA-anticoagulated plasma, any ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due to something other than ACE or another $Zn^{2+}$ metalloprotease.

We performed the ACE2 assay on EDTA-anticoagulated (obtained using clinical standard lavender top tubes) research participant plasma samples obtained at about the 7th day of hospitalization for a cohort of 67 COVID-19 patients with moderate to severe disease. Using these samples, without dilution and without added $Zn^{2+}$, we found that we could detect cleavage of the ACE2 peptide substrate in some of the patients, suggesting that the ACE2 peptide substrate cleavage activity was produced by an agent

with co-factor characteristics different from canonical ACE2 (FIG 3). FIG 4 shows a

scatter plot of the RFU values for the 67 patients studied.

To determine whether the ACE2 substrate cleavage activity was associated with the

presence of immunoglobulin in the samples, we developed an immunoglobulin depletion

protocol that includes an initial 0.45 um filtration step to remove large aggregates,

followed by a 100 KDa size exclusion column chromatography step, and a subsequent

staphylococcal A/G bead absorption step. To test whether patients with high RFU had

ACE2 substrate cleavage activity associated with immunoglobulin, we selected samples

from patients who had RFU values in the top 20% RFU values and which still had

sufficient plasma samples remaining for the immunoglobulin depletion procedure and

subsequent ACE2 assays. This selection yielded samples from 11 patients, 4, 5, 9, 11,

13, 15, 27, 43, 44, 47, and 48. We also selected samples from 3 patients (17, 64, 64)

who were among the patients having the bottom 10% of ACE2 substrate cleavage

activity and for which sufficient sample was available for the immunoglobulin depletion

procedure as negative control. We also included a purchased pooled EDTA-

anticoagulated plasma sample as an additional control.

Table 2 show the results of the immunoglobulin depletion protocol applied to the patient

plasma samples from these patients. The process depleted IgG by a factor of

>>99.99%, leaving IgG in the samples at <2.5 ng/ml for all samples.

We then re-assayed these samples to determine whether immunoglobulin depletion

was associated with elimination of the ACE2 substrate cleavage activity (FIG 5), and

found that for the 11 tested patients with ACE2 substrate cleavage activity in this cohort,

depletion of the immunoglobulin was accompanied by elimination of ACE2 substrate

cleavage activity.

## Discussion

Our experiments indicate that a fraction of patients with COVID-19 have an activity in

plasma capable of cleaving a substrate for ACE2. The ACE2 substrate cleavage activity

has divalent cation requirements different from native ACE2 and collocates with

immunoglobulin presence during an immunoglobulin depletion procedure, suggesting

that these patients may have antibodies with abzyme activity. Since abzymes can have

a broadened substrate specificity compared to the original enzyme that they mirror, it is

possible that abzymes made in response to SARS-COV-2 infection may be able to

cleave a range of substrates, including substrates that form components of important

regulatory cascades, like clotting, blood pressure regulation, and inflammation

processes, which could account for aspects of COVID-19 that cannot be directly

attributed to viral infection and cell and tissue destruction.

Our study had several strengths. We studied a moderate number of patients, with

samples collected prospectively from acutely hospitalized patients with clearly

established COVID-19 relatively early in their disease course, but likely approaching at

least 2 weeks following initial infection. The patients almost certainly were not admitted

immediately following initial infection and the samples were obtained about a week after

admission, providing enough time for the development of an initial antibody response to

SARS-CoV-2 infection. We used a standard, widely-employed kit for ACE2 peptide

substrate cleavage activity, standard size exclusion columns, protein A/G bead

absorption immunoglobulin depletion techniques, and assays for immunoglobulins. The

data showing that the ACE2 substrate cleavage activity was present even when there

was sufficient EDTA to chelate the $Zn^{2+}$ essential for ACE2 activity suggests that the

ACE2 substrate cleavage activity had important characteristics different from native

ACE2. The data that the ACE2 substrate cleavage activity was removed from the

samples following processing with size exclusion columns and absorption with protein

A/G beads suggests that the non- $Zn^{2+}$-requiring ACE2 substrate cleavage activity co-

localizes with immunoglobulin, supporting the hypothesis that the patients with ACE2

substrate cleavage activity may have developed abzymes with this activity.

However, our study has several limitations. We only studied a limited subset of the

patients admitted to our hospital, from patients who consented to the sample banking

and study and for whom sufficient sample volumes were available. A

contemporaneously collected, matched, prospective set of samples from patients

without COVID-19 would have been ideal negative controls, but samples from such

subjects were not obtained as part of the sample banking effort. We also only

conducted the assays on patient samples obtained at a single time, about 7 days after

hospitalization, so we have no data from patients who were discharged, transferred, or

died prior to day 7 of hospitalization. More importantly, in this study we have no data

from patients later in their disease course or following convalescence from the acute

disease. Inflammatory, coagulopathic, and physiologic dysregulatory phenomena

predominate in the later stages of COVID-19 and at least some aspects of PASC and

MIS-C appear to result from immune-mediated phenomena. However, some of these

patients are treated with anti-inflammatory agents, including intravenous

immunoglobulin, which would make the study of these patients for abzyme-like activity

difficult. If abzymes with promiscuous substrate specificities develop in some COVID-19

patients, some of the clinical features of those disorders could potentially be attributed

to abzymes, but this study is not able to directly address such additional hypotheses,

which would require additional work. In addition, since abzymes can show substantial

substrate specificity spread, it is possible that additional patients in our cohort had

abzymes with substrate specificity sufficiently divergent from angiotensinogen that it

was not detectable using our assay. It is also possible that COVID-19 patients develop

anti-RBD antibodies with abzyme-like activity, but that these antibodies have no clinical

significance. Some fraction of normal individuals may have ACE2-like abzyme activity,

but this activity could have been diluted in the purchased pooled normal control plasma.

However, if the abzyme activity in such patients was similar to that observed in the

individual positive patients in this study, that activity would still be ~15% of the activity of

the positive patients, given the prevalence of detectable abzyme activity in our cohort,

and so would have been likely detectable.

Finally, our study is merely associational. It is possible that we depleted some other,

non-immunoglobulin component of COVID-19 patient plasma that has the ability to

cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G

treatment procedure. To unequivocally establish that some COVID-19 patients develop

anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to

isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage

activity, and then characterize those monoclonal antibodies in detail. Such work lies

outside the perimeters of this current study.

Nevertheless, our study offers potential additional insight into some of the difficult-to-

understand clinical features of COVID-19, and if some of the difficult manifestations of

COVID-19 are related to the induction of antibodies with abzyme-like activity, that

finding may suggest new therapeutic interventions. Some other viruses also have also

evolved to use enzymes located on the target host cell surface as their receptors, so it

is conceivable that those other viral infections may also elicit clinically problematic anti-

viral antibodies. The number of spike protein RBDs presented to the immune system in

a natural infection is vastly greater than the number of RBDs presented to the immune

system following vaccination, offering many more opportunities for the induction of wide-

ranging antibody responses, unlike the antigen exposure resulting from vaccination.

While complications following vaccination are very rare and the risk-benefit calculation

greatly favors vaccination, some of the adverse side effects of SARS-CoV-2 vaccines

might also be attributable to the rare induction of anti-RBD antibodies with catalytic

activity.

**Institutional Review Board Statement:** The sample collection protocol was approved

by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens

(HSR #HSR200362).

**Informed Consent Statement:** Informed consent was obtained from all participants

involved in the study.

**Data Availability Statement:** Data is presented in the manuscript and the

supplements. Raw data can be obtained on request.

**Acknowledgments and Funding:** The study was supported by internal funding from

the University of Virginia, including the Manning Fund for COVID-19 Research at UVA

the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease

Research, and the Coulter Foundation, with sample acquisition costs supported by the

HHV-6 Foundation. We thank the study participants for graciously agreeing to be

research participants, and the research support staff who enrolled the study participants

(led by Linda Bailes RN, Allison Raymond RN and Sarah Struchen RN). We also thank

the University of Virginia Biorepository and Tissue Research Facility for processing the

samples used in the study and for providing specimens (Technical Director, Patcharin

Pramoonjago PhD).

**Conflicts of Interest:** The authors declare no conflict of interest.

**Tables and Figures**
408
409
410

**Table 1. Patient Demographic and Clinical Characteristics (cohort previously described in [35])**
(IQR: interquartile range)

| Characteristic | N = 67, median, (IQR) |
|---|---|
| *Age at Admission* | 60 (48, 66) |
| *First Weight (kg)* | 91 (76, 112) |
| Unknown | 1 |
| *Height (m)* | 1.68 (1.60, 1.83) |
| Unknown | 6 |
| *Gender* | |
| Female | 28 (42%) |
| Male | 39 (58%) |
| *Race* | |
| African American | 23 (34%) |
| Native American | 1 (1.5%) |
| Caucasian | 31 (46%) |
| Other | 12 (18%) |
| *Smoking Status* | |
| Current | 1 (2.1%) |
| Former | 14 (29%) |
| Never | 24 (50%) |
| Unknown | 9 (19%) |
| NA | 19 |
| *Need for ICU* | |
| No | 28 (42%) |
| Yes | 39 (58%) |
| *Need for Intubation* | |
| No | 41 (61%) |
| Yes | 26 (39%) |
| *Blood Type* | |
| A- | 2 (4.8%) |
| A+ | 14 (33%) |
| AB+ | 1 (2.4%) |
| B+ | 3 (7.1%) |
| O- | 1 (2.4%) |
| O+ | 21 (50%) |
| Not determined | 25 |
| *Highest Temperature* | |
| <38 | 42 (49%) |
| 101 | 12 (18%) |
| >38.5 | 12 (18%) |
| >40 | 1 (1.5%) |
| *Length of Stay (Days)* | 10 (5, 22) |
| *Time to Death (Days)* | |
| 6 | 1 |
| 10-20 | 2 |
| 20-30 | 3 |
| >30 | 2 ( |
| *Highest D-Dimer* | 605 (280, 2,074) |
| *Highest CRP* | 10 (4, 16) |
| *BMI* | 33 (27, 38) |
| *Need for Vasopressors* | |
| Yes | 44 (66%) |
| *Dexamethasone* | |
| Yes | 41 (61%) |
| *Prednisone* | |
| Yes | 3 (13%) |
| *Methylprednisolone* | |
| Yes | 5 (22%) |
| *Tocilzumab* | |
| Yes | 4 (6%) |
| *Remdesivir* | |
| Yes | 27 (40%) |
| *Creatinine* | 1.00 (0.80, 1.45) |
| *Hgb* | 12.4 (10.8, 13.6) |
| *IFNa3* | 45 (36, 72) |
| Not determined | 45 |
| *Highest Ferritin* | 1277 (7, 7161) |
| Not determined | 5 |
| *Highest Troponin* | |
| <0.04 | 47 (73%) |
| 0.04-0.4 | 12 (18%) |
| >0.6 | 3 (5%) |
| Not determined | 5 |
| *Highest Creatinine* | 1.10 (0.90, 1.80) |

486　Table 2. Plasma IgG concentration before and after antibody depletion for selected
487　patients exhibiting ACE2 substrate cleavage activity in FIG 2, then re-assayed for ACE2
488　substrate cleavage activity with results shown in FIG 4.
489

| Patient (#) | IgG Concentration | | IgG depletion efficiency (%) |
| --- | --- | --- | --- |
| | Pre[a] mg/ml | Post[b] ng/ml | |
| 4 | 14.62 | 0.67 | >99.99% |
| 5 | 12.50 | 1.48 | >99.99% |
| 9 | 24.40 | 0.96 | >99.99% |
| 11 | 75.41 | 0.17 | >99.99% |
| 13 | 26.35 | 2.46 | >99.99% |
| 15 | 13.27 | 2.47 | >99.99% |
| 27 | 10.53 | 2.40 | >99.99% |
| 43 | 29.07 | 0.87 | >99.99% |
| 44 | 11.17 | 2.29 | >99.99% |
| 47 | 13.15 | 1.85 | >99.99% |
| 48 | 12.32 | 2.06 | >99.99% |

491　a: IgG concentration in plasma before antibody depletion
492　b: IgG concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads
493
494

**Figure Legends**

FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-

COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a

potential host cells. The RBD has a partial negative image of ACE2. Some antibodies

against the RBD may then have a conformation sufficiently like ACE2 to have

proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further

suggests that the catalytic activity of some antibodies will have a substrate specificity

like ACE2, but because the negative image of RBD present antibodies is imperfect,

some antibodies with proteolytic activity will have an altered substrate specificity,

potentially affecting multiple proteolytic regulatory cascades.

FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in

undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.

ACE2 is a $Zn^{2+}$ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was

detectable when exogenous ACE2 was added to the plasma, unless $Zn^{2+}$ was also

added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.

Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,

indicating that the activity was specific for ACE2. The findings indicate that no native

ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any

ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should

be due to something other than ACE or another $Zn^{2+}$ metalloprotease.

FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with

COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the

fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus

control samples. Several patients, including the 11 patients we selected for further study

(4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) because they had among the top 20% of RFU

values and had sufficient plasma sample remaining for the immunoglobulin depletion

protocol, showed an ability to cleave ACE2 substrate.  (HDP: commercially purchased

pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2;

HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative

samples).

FIG 4. Scatter plot of the background corrected RFU values for the plasma samples

from the 67 patients evaluated in this study. The top 20% of values are plotted in red,

the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top

20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays

before and after immunoglobulin depletion shown in FIG 5.

FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin

depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,

11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which

we had sufficient plasma for immunoglobulin depletion, before (blue points) and after

(red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by

protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays

before and after immunoglobulin depletion for pooled patient plasma (PPP) negative

controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among

the bottom 10% of RFU values and had sufficient plasma remaining for the

immunoglobulin depletion protocol. The data suggest that for the 11 patients

demonstrating ACE2 substrate cleavage activity in this cohort, the ACE2 substrate

cleavage activity was depleted in an immunoglobulin-associated manner.

FIG 1. FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The
SARS-COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the
surface of a potential host cells. The RBD has a partial negative image of ACE2. Some
antibodies against the RBD may then have a conformation sufficiently like ACE2 to
have proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
suggests that the catalytic activity of some antibodies will have a substrate specificity
like ACE2, but because the negative image of RBD present antibodies is imperfect,
some antibodies with proteolytic activity will have an altered substrate specificity,
potentially affecting multiple proteolytic regulatory cascades.
558
559
560

561
562

FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.
ACE2 is a $Zn^{2+}$ metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
detectable when exogenous ACE2 was added to the plasma, unless $Zn^{2+}$ was also
added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
indicating that the activity was specific for ACE2. The findings indicate that no native
ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
be due to something other than ACE or another $Zn^{2+}$ metalloprotease.
573

574
575

FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus
control samples. We identified plasma from 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44,
47, 48) that showed an ability to cleave ACE2 substrate.  (HDP: commercially
purchased pooled healthy donor plasma; HDP+P.C: HDP with added recombinant
human ACE2; HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma
from negative samples).

584
585

586    FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
587    from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
588    the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
589    20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
590    before and after immunoglobulin depletion shown in FIG 5.
591
592
593

594
595

FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
(red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by
protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
the bottom 10% of RFU values and had sufficient plasma remaining for the
immunoglobulin depletion protocol. The data suggest that for the 11 patients
demonstrating the highest ACE2 substrate cleavage activity in this cohort, the ACE2
substrate cleavage activity was depleted in an immunoglobulin-associated manner.
608

609
610

**References**

1.	Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ, Fry AM, Oliver SE. Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-70. PMC7017962

2.	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. PMC7159299

3.	Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020 Apr 7;323(13):1239-42.

4.	Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK, Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review. Open Forum Infect Dis. 2020 Jun;7(6):ofaa199. PMC7284010

5.	Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020 Sep;7(9):e671-e8. PMC7351397

6.	Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636-43. PMC7869028

7.	Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY, McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA, Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22. PMC8864018

8.	De Rose DU, Pugnaloni F, Calì M, Ronci S, Caoci S, Maddaloni C, Martini L, Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. Viruses. 2022;14(4):750.

9.      Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. Bmj. 2021 Jul 26;374:n1648.

10.     Su Y, Yuan D, Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S.,, Zhang R, Xie, J., Kornilov, S.A., Scherler, K., Pavlovitch-Bedzyk, A.J., Dong, S., Lausted, C., Lee, I.,, Fallen S, Dai, C.L., Baloni, P., Smith, B., Duvvuri, V.R., Anderson, K.G., Li, J., Yang, F., Duncombe,, C.J. M, D.J., Rostomily, C., Troisch, P., Zhou, J., Mackay, S., DeGottardi, Q., May, D.H,, Taniguchi R, Gittelman, R.M, Klinger, M., Snyder, T.M, Roper, R., Wojciechowska, G., Murray, K.,, Edmark R, Evans, S., Jones, L., Zhou, Y., Rowen, L., Liu, R., Chour, W., Algren, H.A, Berrington,, W.R. W, J.A., Cochran, R.A., Micikas, M.E., the ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Petropoulos, C.J., Cole, H.R., Fischer, T.D., Wei, W., Hoon, D.S.B., Price, N.D., Subramanian, N.,, Hill JA, Hadlock, J., Magis, A.T., Ribas, A., Lanier, L.L., Boyd, S.D., Bluestone, J.A., Chu, H., Hood,, L. G, R., Greenberg, P.D., Davis, M.M., Goldman, J.D., Heath, J.R.,. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. 2022.

11.     Hanidziar D, Bittner EA. Hypotension, Systemic Inflammatory Response Syndrome, and COVID-19: A Clinical Conundrum. Anesth Analg. 2020 Sep;131(3):e175-e6. PMC7302068

12.     Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim PB. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021 Jan;21(1):e63-e7. PMC7850225

13.     Koudelka M, Sovová E. COVID-19 Causing Hypotension in Frail Geriatric Hypertensive Patients? Medicina (Kaunas). 2021 Jun 18;57(6). PMC8235779

14.     Hillmeister P, Persson PB. The Kallikrein–Kinin system. Acta Physiologica. 2012;206(4):215-9.

15.     Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol. 2022 Jul;22(7):411-28. PMC8579187

16.     Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, Callewaert H, Feyen JHM, Liesenborghs L, Heylen E, Jansen S, Pereira LCV, Kraisin S, Guler I, Engelen MM, Ockerman A, Van Herck A, Vos R, Vandenbriele C, Meersseman P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Jacquemin M, Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19. eBioMedicine. 2022 2022/09/01/;83:104195.

17.     Carvalho PRd, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides. 2021 2021/01/01/;135:170428.

18.     Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec 19;234(4783):1566-70.

708     19.     Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody.
709     Science. 1986 Dec 19;234(4783):1570-3.
710
711     20.     Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem.
712     2000;69:751-93.
713
714     21.     Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The
715     moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme
716     parameters. Biochemistry. 2011 May 31;50(21):4402-10.
717
718     22.     Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic
719     hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun
720     9;244(4909):1158-62.
721
722     23.     Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov
723     AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.
724
725     24.     Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural
726     catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL
727     fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.
728
729     25.     Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S.
730     Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May
731     30;39(21):6459-65.
732
733     26.     Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon
734     A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis
735     mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun
736     1;180(11):7714-20.
737
738     27.     Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N,
739     Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of
740     antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999
741     Sep;5(9):1044-7.
742
28.     Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN,
Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM,
Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D,
Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific
degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6.
PMC1324791
749
750     29.     Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB,
751     Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov
752     AG. Induction of a protein-targeted catalytic response in autoimmune prone mice:
753     antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan
754     10;45(1):324-30.
755

756    30.    Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic
757    antibodies with a beta-lactamase activity. Ann N Y Acad Sci. 1996 Oct 12;799:172-5.
758

759    31.    Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using
760    an anti-idiotypic antibody as the "internal image" of an enzyme active site. Appl
761    Biochem Biotechnol. 1994 May-Jun;47(2-3):229-37; discussion 37-9.
762

763    32.    Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic
764    antibodies as functional internal images of enzyme active sites: production of a catalytic
765    antibody with a cholinesterase activity. Proc Natl Acad Sci U S A. 1993 Oct
766    1;90(19):8876-80. PMC47463
767

768    33.    Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as
769    functional internal images of enzyme-active sites. Ann N Y Acad Sci. 1995 Mar
770    31;750:265-70.
771

772    34.    Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle
773    B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic
774    antibody mimics proteolytic function of parent antigen. Biochemistry. 2007 Dec
775    18;46(50):14598-609.
776

777    35.    Brooks B, Tancredi C, Song Y, Mogus AT, Huang M-LW, Zhu H, Phan TL, Zhu
778    H, Kadl A, Woodfolk J. Epstein–Barr Virus and Human Herpesvirus-6 Reactivation in
779    Acute COVID-19 Patients. Viruses. 2022;14(9):1872.
780

781    36.    García-Escobar A, Vera-Vera S, Jurado-Román A, Jiménez-Valero S, Galeote G,
782    Moreno R. Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic
783    Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-
784    19. Biomolecules. 2022 Jan 5;12(1). PMC8774087
785

786    37.    Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J,
787    Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS
788    One. 2021;16(9):e0257016. PMC8415618
789

790    38.    Tanna A, Guarino L, Tam FWK, Rodriquez-Cubillo B, Levy JB, Cairns TD, Griffith
791    M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD. Long-term outcome of anti-
792    neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the
793    international histological classification and other prognostic factors. Nephrology Dialysis
794    Transplantation. 2014;30(7):1185-92.
795

796    39.    Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in
797    biological fluid (ACE2).  Hypertension: Springer; 2017. p. 101-15.
798